title: [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
abstract: Since April 2011 fingolimod (FTY 720, Gilenya®), a new oral treatment, is available for relapsing-remitting multiple sclerosis (MS) in Germany. Adverse effects in pre-marketing clinical controlled multicenter studies have led to specific precautions that have to be followed before initiating treatment. According to the European Union prescribing information fingolimod is not to be used as a first-line treatment, but is licensed as a second-line option or escalating therapy of MS. During treatment physical and neurological examinations as well as regular blood counts should be performed. The immunosuppressive mode of action of fingolimod requires increased awareness of infectious complications. Due to two fatal herpetic infections during the TRANSFORMS trial all patients without a history of chicken pox or without vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV. Comparably to other immunosuppressive treatment strategies the immune response to vaccines may be hampered during treatment with fingolimod. Thus, on the one hand, vaccination gaps should be closed before initiation of fingolimod treatment and, on the other hand, success of vaccinations during fingolimod therapy may have to be checked by antibody titre assessment.
authors.affiliation: Klinik und Poliklinik für Neurologie, Universität Rostock, Gehlsheimer Str. 20, 18147, Rostock, Deutschland. alexander.winkelmann@med.uni-rostock.de
authors.forename: A
authors.initials: A
authors.lastname: Winkelmann
authors.forename: M
authors.initials: M
authors.lastname: Löbermann
authors.forename: E C
authors.initials: EC
authors.lastname: Reisinger
authors.forename: U K
authors.initials: UK
authors.lastname: Zettl
mesh_terms: D000068876:Fingolimod Hydrochloride; D006561:Herpes Simplex / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D009103:Multiple Sclerosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D011409:Propylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects*; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine